EPCAM and cancer: To increase the efficacy and specificity of EpCAM treatment, combinatorial approaches have been developed, where the EpCAM antibody is fused with another anticancer molecule that targets a different cancer receptor/ligand, and improves the specificity for cancer cells, such as catumaxomab (Removab), which combines anti-CD33 antibody and anti-EpCAM antibody, and increases the specificity of the therapy [26,27].